Cargando…

Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials

The current meta-analysis aims to assess the efficacy and safety of sodium glucose cotransporter 2 (SGLT2) inhibitors in individuals with diabetes and chronic kidney disease (CKD). The current meta-analysis was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamil, Sidra, Zainab, Arfa, Arora, Avneet Kaur Manjeet Singh, Shaik, Tanveer Ahamad, Khemani, Vimal, Mekowulu, Favour C, Aschalew, Yared N, Khan, Saima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791678/ https://www.ncbi.nlm.nih.gov/pubmed/36579248 http://dx.doi.org/10.7759/cureus.31898

Ejemplares similares

Effect of Statin Therapy on Mortality and Recurrence of Intracerebral Hemorrhage in Patients With Spontaneous Intracerebral Hemorrhage
por: Jamil, Sidra, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
por: Wahinya, Maureen, et al.
Publicado: (2023)

Atorvastatin as a Rare Primary Cause of Drug-Induced Angioedema: A Case Report
por: Voloshyna, Diana, et al.
Publicado: (2022)

Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review
por: Sarker, Aditi, et al.
Publicado: (2022)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

Monkeypox-Associated Pericarditis: A Maiden Case
por: Shaik, Tanveer Ahamad, et al.
Publicado: (2022)

Asymptomatic Hyperuricemia as an Independent Risk Factor for Myocardial Infarction in Adult Population: A Four-Year Follow-Up Study
por: Talpur, Abdul Subhan, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
por: Thiagaraj, Suvedha, et al.
Publicado: (2023)

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review
por: Moparthi, Kiran Prasad, et al.
Publicado: (2023)

Traumatic Carotid Cavernous Fistula Resulting in Symptoms in the Ipsilateral Eye: A Case Report
por: Saleem, Muhammad Salman, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice
por: Erdem, Saliha, et al.
Publicado: (2023)

The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
por: Rehman, Saad U, et al.
Publicado: (2020)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review
por: Kalluri, Sahithi Reddy, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Paradoxical Myocardial Infarction After Thrombolytic Therapy for Acute Ischemic Stroke
por: Mohmand, Billal, et al.
Publicado: (2021)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Comparison of Interrupted and Uninterrupted Anticoagulation Therapy for Patients With Atrial Fibrillation Undergoing Catheter Ablation: A Meta-Analysis
por: Jamil, Sidra, et al.
Publicado: (2022)

Left Ventricular Global Longitudinal Strain in Patients With COVID-19 Infection
por: Bhatti, Harneet, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Role of Cod Liver Oil in Preventing Myocardial Infarction
por: Mal, Madho, et al.
Publicado: (2021)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Conformational Dynamics of hSGLT1 during Na(+)/Glucose Cotransport
por: Loo, Donald D.F., et al.
Publicado: (2006)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m5h9320ep0he90aog2cebkak06